 7. No more than 2 prior chemotherapy regimens are permissible. Patients must have recovered from any toxic effects and at least 3-4 weeks must have elapsed from the last dose and prior to registration 14 days for vinorelbine or other vinca alkaloids or gemcitabine. Patients who, in the opinion of the investigator, have fully recovered from surgery in less than 4 weeks may also be considered for the study. Patients must have recovered CTC 1 from acute toxicities of any previous therapy. 